LXRX Lexicon Pharmaceuticals, Inc.
Healthcare$2.16-3.14%ClosedMarket Cap: $959.5M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
4.26
P/S
13.78
EV/EBITDA
-48.05
DCF Value
$-10.36
FCF Yield
-4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.1%
Operating Margin
-34.8%
Net Margin
-37.5%
ROE
-18.6%
ROA
-9.7%
ROIC
-9.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $21.1M | 99.5% | $-996.0K | $-1.0M | $— | — |
| Q4 null | $5.5M | 94.2% | $-14.8M | $-15.5M | $— | — |
| FY null | $49.8M | 99.4% | $-48.9M | $-50.3M | $— | — |
| Q3 null | $14.2M | 99.9% | $-12.2M | $-12.8M | $— | — |
| Q2 null | $28.9M | 99.3% | $3.7M | $3.3M | $— | — |
| Q1 null | $1.3M | 97.6% | $-25.7M | $-25.3M | $— | — |
| Q4 null | $26.6M | 2.3% | $-32.7M | $-33.8M | $— | — |
| FY null | $31.1M | 98.0% | $-197.1M | $-200.4M | $— | — |
| Q3 null | $1.8M | 95.9% | $-63.7M | $-64.8M | $— | — |
| Q2 null | $1.6M | 89.9% | $-55.4M | $-53.4M | $— | — |
| Q1 null | $1.1M | 84.5% | $-45.3M | $-48.4M | $— | — |
| Q4 2023 | $702.0K | -2012.8% | $-46.7M | $-49.8M | $-0.20 | — |